CompletedNCT04219280
Quillivant XR for ADHD in children with Down syndrome
About this title
Read the official source — NCT04219280Medication studyAges 6–17United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Sacramento and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 2, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT04219280
- Official title
Show the full official title
Evaluating Assessment and Medication Treatment of ADHD in Children With Down Syndrome
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Sacramento · Boston · Cincinnati
1 more locations
- Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Children's Hospital Medical Center, Cincinnati, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Quillivant XR and Placebo.
Who was this study for?
Listed age limits: 6 years to 17 years.
